New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis)

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 5, 2003, Pages 661-669

  Urbina, Julio A ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Chagas disease; Chemotherapy; Cysteine protease inhibitors; Ergosterol biosynthesis inhibitors; Trypanosoma cruzi

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; 4 TERT BUTYL N [1 (4 HYDROXYBENZYL) 2 OXO 2 (3 OXOHEXAHYDROFURO[3,2 B]PYRROL 4 YL)ETHYL]BENZAMIDE; 4 TERT BUTYL N [2 (4 HYDROXYPHENYL) 1 (3 OXO HEXAHYDROCYCLOPENTA [B]FURAN 3A YLAMINOCARBONYL)ETHYL]BENZAMIDE; ANTIPARASITIC AGENT; BENZNIDAZOLE; BENZOFURAN DERIVATIVE; CHLOROQUINE; CLOTRIMAZOLE; CRUZIPAIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DIHYDROFOLATE REDUCTASE INHIBITOR; FURAN 3 CARBOXYLIC ACID [3,3 DIMETHYL 1 (3 METHYL 5 OXO TETRAHYROPYRAN 4 YLAMINOCARBONYL)BUTYL]AMIDE; GYRASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; METAL COMPLEX; N (2 METHYL 4 OXOTETRAHYDROFURAN 3 YL) 4 METHYL 2 [2 OXO 2 (3 PHENYLPYRROL 1 YL)ETHYL]PENTANAMIDE; N [1 (2,3 DIMETHYL 4 OXOTETRAHYDROFURAN 3 YLAMINOCARBONYL) 2 (4 HYDROXYPHENYL)ETHYL] 2 (PYRIDIN 3 YL)THIAZOLE 4 CARBOXAMIDE; N [1 [1 (3 FLUOROBENZENESULFONYL) 3 OXOAZEPAN 4 YLAMINOCARBONYL] 3 METHYLBUTYL]BENZOFURAN 2 CARBOXAMIDE; N [N (4 METHYLPIPERAZIN 1 YLCARBONYL)LEUCYL]TYROSINAL; NIFURTIMOX; PLATINUM COMPLEX; POSACONAZOLE; RAVUCONAZOLE; RHODIUM DERIVATIVE; SEMICARBAZONE DERIVATIVE; SIALIDASE INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHAGAS DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HOST; HUMAN; NONHUMAN; PARASITE SURVIVAL; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 0038446640     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.5.661     Document Type: Review

References (60)

1. WORLD HEALTH ORGANIZATION: Tropical Disease Research. In: Thirteenth Programme Report, UNDP/WorldBank/World Health Organization Programme for Research and Training in Tropical Diseases. World Health Organization, Geneva (1997).
2. SCHMUÑIS GA: A Tripanossomíase Americana e sue impacto na suúde publica das Américas. In: Trypanosoma cruzi e Doença de Chagas. Brener Z, Andrade Z, Barral-Netto M (Eds), Guanabara Koogan, Rio de Janeiro (2000):1-15.
3. WORLD HEALTH ORGANIZATION: Control of Chagas Disease. Technical Reports Series (2002) 905:1-109.
4. PINTO DIAS JC: Epidemiologia. In: Trypanosoma cruzi e doença de Chagas. (2nd Ed.). Brener Z, Andrade Z, Barral-Netto C (Eds), Guanabara Koogan, Rio de Janeiro (1999):48-74.
5. URBINA JA: Specific treatment of Chagas disease: current status and new developments. Curr. Op. Infect. Dis. (2001) 14:733-741.
6. URBINA JA: Chemotherapy of Chagas Disease. Curr. Pharm. Design (2002) 8:287-295.
7. DOCAMPO R: Recent developments in the chemotherapy of Chagas' disease. Curr. Pharm. Design (2001) 7:1157-1164.
8. COURA JR, DE CASTRO SL: A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz (2002) 97:3-24.
9. CANÇADO JR: Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz (1999) 94(Suppl.1):331-336.
10. BRENER Z, GAZZINELLI RT: Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int. Arch. Allergy Immunol. (1997) 114:103-110.
11. URBINA JA: Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med. (1999) 77:332-338.
12. HIRST SI, STAPLEY LA: Parasitology: the dawn of a new millenium. Parasitol. Today (2000) 16:1-3.
13. MOREL CM: Reaching maturity-25 years of the TDR. Parasitol. Today (2000) 16:522-525.
14. TROUILLER P, OLLIARO P, TORREELE E, ORBINSKI J, LAING R, FORD N: Drug development for neglected diseases: a deficient market and public-health policy failure. Lancet (2002) 359:2188-2194.
15. TARLETON RL, ZHANG L: Chagas disease ethiology: autoimmunity or parasite persistence? Parasitol. Today (1999) 15:94-99.
16. TARLETON RL: Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. (2001) 31:550-554.
17. MCKERROW JH, MCGRATH ME, ENGEL JC: The cysteine proteinase of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol Today (1995) 11:279-282.
18. CAZZULO JJ: Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr. Pharm. Design (2002) 2:1261-1271.
19. CAZZULO JJ, STOKA V, TURK V: The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr.Pharm. Design (2001) 7:1143-1156.
20. ENGEL JC, DOYLE PS, HSIEH I, MCKERROW JH: Cysteine protease inhibitors cure experimental Trypanosma cruzi infection. J. Exp. Med. (1998) 188:725-734.
21. ENGEL JC, DOYLE PS, MCKERROW JH: Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease. Medicina (1999) 59(Suppl.II):171-175.
22. DU X, HANSELL E, ENGEL JC, CAFFREY CR, COHEN FE, MCKERROW JH: Aryl ureas represent a new class of anti-trypanosomal agents. Chem. Biol. (2000) 7:733-742.
23. DU X, GUO C, HANSELL E et al.: Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. (2002) 45:2695-2707.
24. URBINA JA: Sterol biosynthesis inhibitors for Chagas' disease. Curr. Op. Anti-infect. Inv. Drugs (2000) 2:40-46.
25. URBINA JA: Parasitological cure of Chagas disease: is it possible, is it relevant? Mem. Inst. Oswaldo Cruz (1999) 94(Suppl.1):349-355.
26. URBINA JA, PAYARES G, MOLINA J et al.: Cure of short- and long-term experimental Chagas disease using D0870. Science (1996) 273:969-971.
27. URBINA JA, PAYARES G, SANOJA C et al.: Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Intern. J. Antimicrob. Agents (2003) 21:39-48.
28. MOLINA J, MARTINS-FILHO O, BRENER Z, ROMANHA AJ, LOEBENBERG D, URBINA JA: Activity of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. (2000) 44:150-155.
29. MOLINA J, BRENER Z, ROMANHA AJ, URBINA JA: In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. Effects of immunosuppresion. J. Antimicrob. Chemother. (2000) 46:137-140.
30. URBINA JA, PAYARES G, SANOJA C, LIRA R, ROMANHA AJ: In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Intern. J. Antimicrob. Agents (2003) 21:27-38.
31. MARTIN MB, ARNOLD W, HEATH III HT, URBINA JA, OLDFIELD E: Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biopbys. Res. Comm. (1999) 263:754-758.
32. DUNFORD JE, THOMPSON K, COXON FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exper. Therapeutics (2001) 296:235-242.
33. MONTALVETTI A, BAILEY BN, MARTIN MB, SEVERIN GW, OLDFIELD E, DOCAMPO R: Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. (2001) 276:33930-33937.
34. AMIN D, CORNELL SA, GUSTAFSON SK et al.: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res. (1992) 33:1657-1663.
35. AMIN D, CORNELL SA, PERRONE MH, BILDER GE: 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as potent inhibitor of squalene synthase. Drug Res. (1996) 46:759-762.
36. RESZKA AA, HALASY-NAGY J, RODAN GA: Nitrogen-bisphosphonates block retinoblastoma phosphotylation and cell growth by inhibiting the cholesterol biosymthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. (2001) 59:193-202.
37. URBINA JA, CONCEPCION JL, CALDERA A, LIRA R, PAYARES G, SANOJA C: In vitro and in vivo activities of ER-27856, a novel squalene synthase inhibitor, against Trypanosoma cruzi, the causative agent of Chagas disease. ICAAC Abstracts (2002) 42:LB-25.
38. DOCAMPO R, MORENO SNJ: Bisphosphonates as chemotherapeutic agents against Trypanosomatid and Apicomplexan parasites. Curr. Drug Targets-Infec. Disord. (2001) 1:51-61.
39. 2+ storage compartment in Trypanosomatids and Apicomplexan parasites. Parasitol. Today (1999) 15:443-448.
40. DOCAMPO R, MORENO SNJ: The acidocalcisome. Mol. Biochem. Parasitol. (2001) 33:151-159.
41. BUCKNER FS, GRIFFIN JH, WILSON AJ, VAN VOORHIS WC: Potent anti-Trypanosma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother. (2001) 45:1210-1215.
42. BUCKNER FS, NGUYEN LN, JOUBERT BM, MATSUDA SP: Cloning and expression of the Trypanosoma brucei lanosterol synthase gene. Mol. Biochem. Parasitol. (2000) 110:399-403.
43. JOUBERT BM, BUCKNER FS, MATSUDA SP: Trypanosome and animal lanosterol synthases use different catalytic motifs. Org. Lett. (2001) 14:1957-1960.
44. ZUCCOTTO F, MARTIN AC, LASKOWSKI RA, THORNTON JM, GILBERT IH: Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania. J. Comput. Aided Mol. Des. (1998) 12:241-257.
45. GILBERT IH: Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim. Biophys. Acta (2002) 587:249-257.
46. RECHE P, ARREBOLA R, OLMO A, SANTI DV, GONZALEZ-PACANOWSKA D, RUIZ-PEREZ LM: Cloning and expression of the dihydrofolate reductase-thymidylate synthase gene from Trypanosoma cruzi. Mol. Biochem. Parasitol. (1994) 65:247-258.
47. RECHE P, ARREBOLA R, SANTI DV, GONZALEZ-PACANOWSKA D, RUIZ-PEREZ LM: Expression and charecterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol. Biochem. Parasitol. (1996) 76:175-185.
48. CROFT SL, HOGG J: Limited activity of bacterial DNA topoisomerase II inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Trans. Roy. Soc. Trop. Med. Hyg. (1988) 82:656.
49. FURET YX, PECHERE JC: Newly documented antimicrobial activity of quinolones. Eur. J. Clin. Microbiol. Infect. Dis. (1991) 10:249-254.
50. GONZALEZ-PERDOMO M, DE CASTRO SL, MEIRELLES MNL, GOLDENBERG S: Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob. Agents Chemother. (1990) 34:1707-1714.
51. NENORTAS E, BURRI C, SHAPIRO TA: Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Chemother. (1999) 43:2066-2068.
52. FARRELL NP, WILLIAMSON J, MCLAREN DJ: Trypanocydal and anti-tumor activity of platimun-metal and platinum-metal-drug dual function complexes. Biochem. Pharmacol. (1984) 33:961-971.
53. 2. J. Med. Chem. (1993) 36:2041-2043.
54. SANCHEZ-DELGADO RA, NAVARRO M, PEREZ H, URBINA JA: Towards a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. J. Med. Chem. (1996) 39:1095-1099.
55. SANCHEZ-DELGADO RA, NAVARRO M, LAZARDI K et al.: Towards a novel metal based chemotherapy against tropical diseases. 4. Synthesis and characterization of new metal-clotrimazole complexes and evaluation of their activity against Trypanosoma cruzi. Inorg. Chim. Acta (1998) 275-276:528-540.
56. PEREIRA-CHIOCCOLA VL, SCHENKMAN S: Biological role of Trypanosoma cruzi trans-sialidase. Biochem. Soc. Trans. (1999) 27:516-518.
57. FRASCH AC: Functional diversity in the trans-sialidase family and mucin families in Trypanosoma cruzi. Parasitol. Today (2000) 16:282-286.
58. BUCHIAZZO A, AMAYA MF, CREMONA ML, FRASCH AC: The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol. Cell (2002) 10:757-768.
59. 2+ release from acidocalcisomes of Trypanosoma brucei. Biochem. J. (1996) 315:265-270.
60. + exchanger in acidocalcisomes of Leishmania donovani and their alkalinization by anti-leishmanial drugs. FEBS Lett.